HedyLKindlerMD

Oncology • Chicago, IL

Hematologic Oncology, Thoracic Cancer

Professor of Medicine and Associate Dean for Clinical Science Research, University of Chicago

Join to view full profile

Dr. Kindler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kindler's full profile

Already have an account?

Office
5841 S Maryland Ave, MC 2115
Chicago, IL 60637
Phone+1 773-702-0360

Fax+1 773-702-3163

Summary

Dr. Hedy Kindler is an oncologist specializing in mesothelioma, based in Chicago, IL. She completed her medical education at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and underwent residency training at UCLA and Montefiore Medical Center, followed by a fellowship at Memorial Sloan Kettering Cancer Center. Dr. Kindler currently practices at the University of Chicago Pritzker School of Medicine where she is a Professor of Medicine and Associate Dean for Clinical Science Research. She is experienced in pleural, peritoneal, and tunica vaginalis mesothelioma. She has been recognized as a top doctor by various organizations and has published numerous articles on mesothelioma and cancer treatment. Her involvement in clinical trials includes studies on mesothelioma and evaluating novel therapies.

Clinical Expertise

Mesothelioma, Clinical research

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1991 - 1992
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1989 - 1991
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1989

Certifications & Licensure

IL State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Chicago Magazine: Top Doctors Castle Connolly, 2008-2024
Wagner Medal International Mesothelioma Interest Group, 2023
Pioneer Award Mesothelioma Applied Research Foundation, 2022
Fellow of the American Society of Clincial Oncology American Society of Clinical Oncology, 2018
Dr. Irving Selikof Lfetime Achievement Award Asbestos Disease Awareness Organization, 2010
Join now to see all

Clinical Trials

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer Start of enrollment: 1996 Nov 01
Completed
Phase 1
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus Start of enrollment: 1998 Mar 01
Completed
Phase 2
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Start of enrollment: 1999 Jan 01
Completed
Phase 2
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 1999 Feb 01
Completed
Phase 2
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer Start of enrollment: 1999 Apr 01
Withdrawn
Phase 2
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 2
Capecitabine in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Nov 01
Completed
Phase 2
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Start of enrollment: 2000 Aug 01
Terminated
Phase 2
SU5416 in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Aug 01
Completed
Phase 2
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 2
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Start of enrollment: 2001 Aug 01
Terminated
Phase 2
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Start of enrollment: 2001 Oct 01
Completed
Phase 2
Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer Start of enrollment: 2002 Feb 01
Completed
Phase 2
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine Start of enrollment: 2003 Feb 01
Completed
Phase 2
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Start of enrollment: 2003 Jul 01
Completed
Phase 2
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 3
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma Start of enrollment: 2004 Feb 01
Completed
Phase 2
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Start of enrollment: 2003 Apr 01
Completed
Phase 1, Phase 2
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate Start of enrollment: 2005 Sep 14
ACTIVE_NOT_RECRUITING
PHASE2
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma Start of enrollment: 2008 Mar 01
Unknown status
Phase 2
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Start of enrollment: 2009 Sep 03
COMPLETED
PHASE2
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma Start of enrollment: 2011 Aug 23
Completed
Phase 1
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Start of enrollment: 2008 Jul 02
RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2012 May 15
ACTIVE_NOT_RECRUITING
PHASE2
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Start of enrollment: 2012 Jun 01
Completed
Phase 2
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Start of enrollment: 2012 Mar 26
Completed
Phase 1
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Start of enrollment: 2013 Oct 09
Completed
Phase 1
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Start of enrollment: 2014 Dec 16
Completed
Phase 3
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Start of enrollment: 2015 Jan 20
Completed
Phase 2
Pembrolizumab in Treating Patients With Malignant Mesothelioma Start of enrollment: 2015 Mar 31
Active, not recruiting
Phase 2
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) Start of enrollment: 2015 Dec 03
Completed
Phase 2
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Start of enrollment: 2015 Dec 18
RECRUITING
PHASE2
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Start of enrollment: 2016 Feb 03
Completed
Phase 1
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Start of enrollment: 2016 Feb 25
TERMINATED
PHASE1
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Start of enrollment: 2016 Sep 01
Terminated
Phase 1
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study Start of enrollment: 2016 Jun 28
Terminated
Phase 1
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08
ACTIVE_NOT_RECRUITING
PHASE3
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas Start of enrollment: 2018 Oct 10
RECRUITING
PHASE1
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2019 May 10
COMPLETED
PHASE3
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer Start of enrollment: 2020 Jan 31
ACTIVE_NOT_RECRUITING
PHASE3
Olaparib in Patients With HRD Malignant Mesothelioma Start of enrollment: 2021 Feb 19
RECRUITING
PHASE2
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Start of enrollment: 2019 Apr 16
Completed
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Convolutional Neural Networks for Segmentation of Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance).
Mena Shenouda, Eyjólfur Gudmundsson, Feng Li, Christopher M Straus, Hedy L Kindler
Journal of Imaging Informatics in Medicine. 2025-04-01
2 citations
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Hedy L Kindler, Nofisat Ismaila, Lyudmila Bazhenova, Quincy Chu, Jane E Churpek
Journal of Clinical Oncology. 2025-03-10
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Hedy L Kindler, Ibiayi Dagogo-Jack, Marc de Perrot, Michael W Drazer, Nofisat Ismaila
JCO Oncology Practice. 2025-03-07

Journal Articles

Dynamic Contrast-Enhanced CT for the Assessment of Tumour Response in Malignant Pleural Mesothelioma: A Pilot Study
Hedy L Kindler, Christopher M Straus, European Radiology

Other

A Glimmer of Hope for Pancreatic Cancer
Hedy Kindler, MD, The New England Journal of Medicine
https://www.doximity.com/articles/4da358e8-3072-4a10-8624-6ba76937ef66
UpToDate, Wolters Kluwer Health - 2012-08-30

Authored Content

Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018

Press Mentions

Top Mesothelioma Cancer Center in Chicago Adding New FacilityMarch 22nd, 2022
Added Anti-VEGFR2 Antibody Boosts Survival in MesotheliomaSeptember 8th, 2021
Mesothelioma Olaparib Clinical Trial Targets Genetic MutationAugust 24th, 2021
Join now to see all

Grant Support

UG1 - NCTN (Network Lead)UNIVERSITY OF CHICAGO2019–2025
NCI National Clinical Trials Network Lead Academic Participating SiteNIH2014–2019
PI3K as a Therapeutic Target in Malignant Pleural MesotheliomaDepartment of Defense2012–2014
Cancer And Leukemia Group BNational Cancer Institute2009–2012
Novel Targeted Therapy In Pancreatic CancerNational Cancer Institute2009–2010